Two young women, 22 and 33 years old, presented with uncontrollable muscle jerks involving the torso, neck, and extremities; dystonic posturing in the extremities or neck; and anosmia. Both were diagnosed with COVID-19 three to four weeks before presentation. However, the 22-year-old remained positive and the 33-year-old was negative at presentation. Their myoclonus was triggered by voice and worsened with intention and action but decreased while laying quietly and stopped during sleep. Both were taking psychoactive medications for years without side effects. Strength, reflexes, and plantar response were normal, as were labs. CSF analysis was normal for the 33-year-old. LP was not performed in the 22-year-old due to increased risk of CSF leaks in patients with Ehlers Danlos syndrome. Non-contrast MRI brain was normal in both. All medications with potential interactions were discontinued. Both were given IV fluids and cyproheptadine without improvement. A hyper-serotonergic state and all other causes of myoclonus were ruled out. Both were started on high dose intravenous methylprednisolone, clonazepam, and IVIG. The 33-year-old exhibited dramatic resolution of her myoclonus by the end of the treatment. The 22-year-old developed bradycardia, prompting discontinuation of methylprednisolone and clonazepam. She had modest improvement after completing IVIG but by discharge had near complete resolution of her myoclonus.